This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Penumbra (PEN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 25.76% and 2.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Integer (ITGR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes Care (TNDM) Moves 7.6% Higher: Will This Strength Last?
by Zacks Equity Research
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
by Zacks Equity Research
PEN continues to attract investor interest with its strong Thrombectomy business and portfolio expansion efforts.
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues
by Zacks Equity Research
Penumbra expects to materially increase both revenues and profitability in the company's international business in the next few years.
Penumbra (PEN) Down 8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail
by Zacks Equity Research
Penumbra is still in the early stages of its journey to bring the company's proprietary thrombectomy technologies to patients in the United States and around internationally.
BAX Stock Surges Following Q4 Earnings & Sales Beat, Margins Decline
by Zacks Equity Research
Baxter reports better-than-expected fourth-quarter results. However, the company's gross and operating margins contract. Shares rise in pre-market.
Penumbra (PEN) Upgraded to Buy: Here's Why
by Zacks Equity Research
Penumbra (PEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises
by Zacks Equity Research
Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.
Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings
by Zacks Equity Research
The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Penumbra (PEN) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 6.59% and 1.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
ZBH Stock Hurt by Margin Concerns and Difficult Solvency
by Zacks Equity Research
Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.
DexCom Stock Rises Despite Q4 Earnings Miss & Lower Margins
by Zacks Equity Research
DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
HOLX's New Offerings Likely to Revive Stock Amid Macro Woes
by Zacks Equity Research
Hologic's Surgical business has been recording strong broad-based performance by expanding access to technologies into new global markets.
TMO Stock Set to Gain From The Launch of New Spatial Imaging System
by Zacks Equity Research
Thermo Fisher's Invitrogen EVOS S1000 Spatial Imaging System addresses the limitations of current fluorescent microscopy technologies.
ALGN Stock Gains on the Launch of Invisalign Palatal Expander in Turkey
by Zacks Equity Research
Align Technology commercially launches its Invisalign Palatal Expander System in Turkey after approval from TMMDA.
Should You Add Penumbra Stock to Your Portfolio Right Now?
by Zacks Equity Research
PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.
Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain?
by Zacks Equity Research
GMED is set to acquire all shares of Nevro in an all-cash transaction, unlocking new growth opportunities.
Hologic (HOLX) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 0.98% and 0%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
COR Stock Gains on Q1 Earnings & Revenue Beat & Upbeat '25 Outlook
by Zacks Equity Research
COR's first-quarter fiscal 2025 results showcase a strong segmental performance. The company's sales and earnings guidance for fiscal 2025 looks encouraging.
RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust
by Zacks Equity Research
Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.